| Prev Close | 27.59 |
| Open | 27.84 |
| Day Low/High | 27.69 / 28.10 |
| 52 Wk Low/High | 16.56 / 29.44 |
| Volume | 1.41M |
| Avg Volume | 1.97M |
Horizon Therapeutics Plc (HZNP)
27.97
0.38
1.38
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 186.45M |
| Market Cap | 5.03B |
| EPS | -0.50 |
| P/E Ratio | 70.51 |
| Div & Yield | N.A. (N.A) |
Latest News
VMware and Chevron Are Among 11 Well-Known Stocks Ready to Change Direction
These names are showing bullish and bearish technical patterns over the past week.
Horizon Shares Rise on Q3 Results, Guidance -- Biotech Movers
The Dublin firm on Nov. 6 unveiled third-quarter numbers that topped analysts' estimates and raised its full-year net sales outlook and the lower end of its 2017 adjusted Ebitda guidance.
Closing Bell: Volatility at Lowest Since 1993; Pershing Backs Howard Hughes
Volatility sank to its lowest level since 1993 to begin the new week as indexes held close to their flatlines.
Bears Are Losing Their Grip on Horizon Pharma
The stock is slowly building a bullish setup.
Horizon Pharma Tanks on Failed Late-Stage Study
Horizon's nueromuscular disorder treatment trials failed.
How Do the Charts Look for Jim Cramer's Weekly Shopping List?
No matter who wins the election, there are ways to make money.
Closing Bell: Fed's Brainard Cautions 'Prudence'; U.S. Stocks Soar
Relief flooded Wall Street after a number of Fed speakers took a dovish turn following increasingly hawkish rhetoric.
Tweets on the Street: Pimco's Eurozone Concerns, Shkreli on Horizon Pharma
Social media chatter also included takes by Michael Bloomberg and Warren Buffett on small-business success.
A Move Lower Is on the Horizon (Pharma)
Don't be surprised if HZNP trends lower to next chart support around $10.
Horizon Pharma Needs a Health Check
HZNP could work lower to $10 in the weeks and months ahead.
Cramer: Collateral Damage Is Giving These Stocks a Bad Name
But for the brave, they could offer a solid bottom-fishing opportunity.
Jim Cramer Recommends Ford Over General Motors Among Autos
Automakers are reporting sales results today, and Ford is Jim Cramer’s top pick in the auto sector.
Silly Season Continues for Biotech
Valuations of some small-cap concerns, such as Relypsa, are ridiculously cheap.
With Martin Shkreli Long Gone, Retrophin is an 'Interesting Opportunity'
Retrophin (RTRX), the biotech company that used to be run by indicted hedge fund manager Martin Shkreki, provides an interesting investment opportunity.
Jim Cramer Says Don't Rush in to Buy Stocks in Monday Selloff
Jim Cramer says don’t rush into the stock market in Monday's trading session looking for bargains in the midst of a selloff.
Bah Humbug Macy's, Jim Cramer Says the Holiday Season Belongs to Amazon
Jim Cramer, portfolio manager at TheStreet’s Action Alerts PLUS and host of CNBC’s ‘Mad Money’ said Amazon (AMZN) stock is going higher because the company’s business model is so good.
Why Biotech Has Bottomed
Investors should ignore the temporary issues that have knocked the sector down.
Why Biotech Has Bottomed
Investors should ignore the temporary issues that have knocked the sector down.
Targets of Market Hatred Can Change Daily
It used to be industrials, now it's health care.
Jim Cramer Says Tech Giants Microsoft, IBM Should Make Acquisitions
Jim Cramer says Microsoft (MSFT) will report a decent quarter, thanks to Windows 10, but he wishes the company would make an acquisition.
A Small Pharma Stock With Big Potential
Pernix looks poised for a strong 2016.
How to Build a Good Foundation in Biotechs
A so-called "pyramid strategy" can help you enter the depressed sector.
Hedge Funds Doing Battle Over Ailing Stocks
There's blood in the water.
The Biotechs Are Being Taken Out and Shot
All you can do is wait until they bottom out.
Horizon and ANI Appeal in Pharma Selloff
Some smaller biotechs offer good value at current levels.
Market Wrap: Stocks Sink Across the Board
Materials and technology names led the way down on the session.
